Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M126688-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $86.90 | |
M126688-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $151.90 | |
M126688-50mg | 50mg | In stock | $489.90 | |
M126688-250mg | 250mg | In stock | $2,205.90 | |
M126688-1g | 1g | In stock | $7,938.90 | |
M126688-5g | 5g | In stock | $35,721.90 | |
M126688-25g | 25g | In stock | $160,744.90 |
Potent and selective β3agonist
Synonyms | 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)- | NCGC00386239-01 | A816162 | CHEBI:92250 | Q3702534 | AB01565808_02 | MFCD02102216 | Myrbetriq (TN) | s4009 | UNII-868YEO5270 | YM 178;2-(2-aminothiazol-4-yl)-N-[4-[ |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Potent and selective β3-adrenoceptor agonist (EC50= 22.4 nM). Displays >440-fold selectivity for β3over β1and β2adrenoceptors. Increases cAMP concentration in CHO cells expressing human β3-adrenoceptor. Displays relaxant effect inex vivorat bladder muscle |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Beta-3 adrenergic receptor agonist |
Product Description | A potent bladder relaxant and reagent for diabetes remedy. |
ALogP | 2.1 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide |
---|---|
INCHI | InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 |
InChi Key | PBAPPPCECJKMCM-IBGZPJMESA-N |
Canonical SMILES | C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O |
Isomeric SMILES | C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O |
PubChem CID | 9865528 |
Molecular Weight | 396.51 |
ChEBI | CHEBI:65349 |
---|---|
CAS Registry No. | 223673-61-8 |
PubChem CID | 9865528 |
ChEMBL Ligand | CHEMBL2095212 |
DrugBank Ligand | DB08893 |
Wikipedia | Mirabegron |
PEP | mirabegron |
Reactome Reaction | R-HSA-9611839 |
Reactome Drug | R-ALL-9611838 |
RCSB PDB Ligand | H6U |
DrugCentral Ligand | 4382 |
GPCRdb Ligand | mirabegron |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2215379 | Certificate of Analysis | Apr 07, 2024 | M126688 |
G2215380 | Certificate of Analysis | Apr 07, 2024 | M126688 |
G2215381 | Certificate of Analysis | Apr 07, 2024 | M126688 |
G2215777 | Certificate of Analysis | Apr 07, 2024 | M126688 |
G2215778 | Certificate of Analysis | Apr 07, 2024 | M126688 |
H1505066 | Certificate of Analysis | Mar 16, 2023 | M126688 |
A2128196 | Certificate of Analysis | Dec 08, 2022 | M126688 |
L2209023 | Certificate of Analysis | Jun 01, 2022 | M126688 |
L2209024 | Certificate of Analysis | Jun 01, 2022 | M126688 |
L2209025 | Certificate of Analysis | Jun 01, 2022 | M126688 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 39.65, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 7.93, Max Conc. mM: 20 |
---|
Pictogram(s) | GHS08, GHS09, GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H319:Causes serious eye irritation H351:Suspected of causing cancer H373:Causes damage to organs through prolonged or repeated exposure H302:Harmful if swallowed H317:May cause an allergic skin reaction H410:Very toxic to aquatic life with long lasting effects H361:Suspected of damaging fertility or the unborn child H371:May cause damage to organs H362:May cause harm to breast-fed children |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P273:Avoid release to the environment. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P272:Contaminated work clothing should not be allowed out of the workplace. P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention. P362+P364:Take off contaminated clothing and wash it before reuse. P391:Collect spillage. P330:Rinse mouth. P263:Avoid contact during pregnancy/while nursing. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P337+P317:If eye irritation persists: Get medical help. P308+P316:IF exposed or concerned: Get emergency medical help immediately. P319:Get medical help if you feel unwell. |
1. Yutao Lou, Mengting Cheng, Qin Cao, Kening Li, Hui Qin, Meihua Bao, Yuan Zhang, Sisi Lin, Yiwen Zhang. (2023) Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (115937). [PMID:38198885] [10.1016/j.jpba.2023.115937] |
1. Yamaguchi O. (2002) Beta3-adrenoceptors in human detrusor muscle.. Urology, 59 (5 Suppl 1): (25-9). [PMID:12007519] [10.1021/op500134e] |
2. Nomiya M, Yamaguchi O. (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.. J Urol, 170 (2 Pt 1): (649-53). [PMID:12853849] [10.1021/op500134e] |
3. Badawi JK, Seja T, Uecelehan H, Honeck P, Kwon ST, Bross S, Langbein S. (2007) Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines.. Urology, 69 (4): (785-90). [PMID:17445682] [10.1021/op500134e] |
4. Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS. (2018) Mirabegron: potential off target effects and uses beyond the bladder.. Br J Pharmacol, 175 (21): (4072-4082). [PMID:29243229] [10.1021/op500134e] |
5. Yutao Lou, Mengting Cheng, Qin Cao, Kening Li, Hui Qin, Meihua Bao, Yuan Zhang, Sisi Lin, Yiwen Zhang. (2023) Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (115937). [PMID:38198885] [10.1016/j.jpba.2023.115937] |